Hem › Follikulärt lymfom › Massachusetts › Boston
Kliniska studier för Follikulärt lymfom i Boston, MA
17 studier för Follikulärt lymfom söker deltagare vid platser i och runt Boston (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
RekryterarFas 3
- Tufts Medical Center, Boston
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekryterarFas 1/2
- Dana Farber Cancer Institute, Boston
Epco, Zanu, Ritux for R/R FL or MZL
RekryterarFas 2
- Dana-Farber Cancer Institute, Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RekryterarFas 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekryterarFas 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
RekryterarFas 3
- Research Site, Boston
- Research Site, Boston
NEO100 and High-Grade Meningioma
RekryterarFas 2
- Tufts Medical Center, Boston
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
RekryterarFas 3
- Beth Israel Deaconess Medical Center, Boston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RekryterarFas 3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RekryterarFas 2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
RekryterarFas 3
- Local Institution - 0145, Boston
- Local Institution - 0244, Boston
- Local Institution - 0247, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RekryterarFas 1
- Massachusetts General Hospital, Boston
Odronextamab in Low Tumor Volume Advanced FL
RekryterarFas 2
- Beth Israel Deaconess Medical Center, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RekryterarFas 2
- Beth Israel Deaconess Medical Center, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
RekryterarFas 1
- Beth Israel Deaconess Medical Center, Boston
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
RekryterarFas 1/2
- Dana Farber Cancer Institute, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RekryterarFas 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Follikulärt lymfom-studier i andra städer
- New York City, NY24 studier
- Milwaukee, WI19 studier
- Nashville, TN18 studier
- Houston, TX18 studier
- Baldwin Park, CA16 studier
- Seattle, WA15 studier
- Durham, NC15 studier
- Columbus, OH13 studier
- Salt Lake City, UT13 studier
- San Antonio, TX12 studier
- Chicago, IL12 studier
- Philadelphia, PA12 studier
Andra studier i Boston
- Bröstcancer111 studier
- Icke-småcellig lungcancer90 studier
- Cancer (alla typer)86 studier
- Kolorektal cancer63 studier
- Metastaserande cancer63 studier
- Lungcancer62 studier
- Äggstockscancer61 studier
- Prostatacancer59 studier
- Depression52 studier
- Endometriecancer50 studier
- Hjärtsvikt44 studier
- Akut myeloid leukemi44 studier
Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.